These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New roles for the BLyS/BAFF family in antigen-experienced B cell niches. Goenka R; Scholz JL; Sindhava VJ; Cancro MP Cytokine Growth Factor Rev; 2014 Apr; 25(2):107-13. PubMed ID: 24507939 [TBL] [Abstract][Full Text] [Related]
5. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Mackay F; Silveira PA; Brink R Curr Opin Immunol; 2007 Jun; 19(3):327-36. PubMed ID: 17433868 [TBL] [Abstract][Full Text] [Related]
6. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Cancro MP Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii34-6. PubMed ID: 17038469 [TBL] [Abstract][Full Text] [Related]
8. The role of BAFF and APRIL in rheumatoid arthritis. Shabgah AG; Shariati-Sarabi Z; Tavakkol-Afshari J; Mohammadi M J Cell Physiol; 2019 Aug; 234(10):17050-17063. PubMed ID: 30941763 [TBL] [Abstract][Full Text] [Related]
9. [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis]. Chang Y; Wei W Yao Xue Xue Bao; 2013 Jul; 48(7):979-85. PubMed ID: 24133964 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. Do RK; Hatada E; Lee H; Tourigny MR; Hilbert D; Chen-Kiang S J Exp Med; 2000 Oct; 192(7):953-64. PubMed ID: 11015437 [TBL] [Abstract][Full Text] [Related]
14. BAFF and associated TNF superfamily members in renal transplantation: an end to BLySful ignorance. Chhabra M; Conlon TM; Saeb-Parsy K; Pettigrew GJ Transplantation; 2013 Nov; 96(10):853-9. PubMed ID: 23774811 [TBL] [Abstract][Full Text] [Related]
16. The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis. Abe T; AlSarhan M; Benakanakere MR; Maekawa T; Kinane DF; Cancro MP; Korostoff JM; Hajishengallis G J Immunol; 2015 Aug; 195(4):1427-35. PubMed ID: 26150532 [TBL] [Abstract][Full Text] [Related]
18. Space, selection, and surveillance: setting boundaries with BLyS. Miller JP; Stadanlick JE; Cancro MP J Immunol; 2006 Jun; 176(11):6405-10. PubMed ID: 16709796 [TBL] [Abstract][Full Text] [Related]
19. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594 [TBL] [Abstract][Full Text] [Related]
20. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Jelinek DF; Darce JR Curr Dir Autoimmun; 2005; 8():266-88. PubMed ID: 15564725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]